logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
J

Jason M. Pogue

glaxosmithkline

52H-index
263Paper Count
1.0WCitation Count
Published Papers 123
Publication Date
logo
Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies
errClinical Infectious Diseases
IF7.3
err2026-02-01
err0
errOAAI
errSheets, Amanda J.; Dennison, Jeremy; Pogue, Jason M.; Kaye, Keith S.; Perry, Caroline; Millns, Helen; Diaz-Reganon, Jazmin; Janmohamed, Salim
errShare
errSave
First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa
errCLINICAL INFECTIOUS DISEASES
IF7.3
err2025-12-01
err1
PREAI
errDorazio, Ava J.; Aitken, Samuel L.; Pierce, Virginia M.; Kline, Ellen G.; Squires, Kevin M.; Pogue, Jason M.; Shields, Ryan K.
errShare
errSave
Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and Pseudomonas aeruginosa
errOPEN FORUM INFECTIOUS DISEASES
IF3.8
err2025-12-01
err0
PREAI
errBhavnani, Sujata M.; Hammel, Jeffrey P.; Onufrak, Nikolas J.; Pogue, Jason M.; Jones, Ronald N.; Sader, Helio S.; Drusano, George L.; Bradley, John S.; Andes, David R.; Craig, William A.; Ambrose, Paul G.
errShare
errSave
Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and Pseudomonas aeruginosa: Brief Summary
errOPEN FORUM INFECTIOUS DISEASES
IF3.8
err2025-12-01
err0
errOAAI
errBhavnani, Sujata M.; Hammel, Jeffrey P.; Onufrak, Nikolas J.; Pogue, Jason M.; Jones, Ronald N.; Sader, Helio S.; Drusano, George L.; Bradley, John S.; Andes, David R.; Craig, William A.; Ambrose, Paul G.
errShare
errSave
The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens
errCLINICAL INFECTIOUS DISEASES
IF7.3
err2025-11-01
err1
PREAI
errHuralska, Mariya; Pogue, Jason M.; Rybak, Michael; Abdul-Mutakabbir, Jacinda C.; Stamper, Kyle; Marchaim, Dror; Thamlikitkul, Visanu; Carmeli, Yehuda; Chiu, Cheng-Hsun; Daikos, George; Dhar, Sorabh; Durante-Mangoni, Emanuele; Gikas, Achilles; Kotanidou, Anastasia; Paul, Mical; Roilides, Emmanuel; Samarkos, Michael; Sims, Matthew; Tancheva, Dora; Tsiodras, Sotirios; Kett, Daniel H.; Patel, Gopi; Calfee, David P.; Leibovici, Leonard; Power, Laura; Munoz-Price, Silvia; Shaikh, Hamadullah; Susick, Laura; Latack, Katie; Chiou, Christine; Divine, George; Ghazyaran, Varduhi; Kaye, Keith S.
errShare
errSave
Actually, It May be Time to Return to Colistin and Meropenem in Some Patients Infected With Carbapenem-resistant A. baumannii (CRAB)
errCLINICAL INFECTIOUS DISEASES
IF7.3
err2025-10-01
err0
PREAI
errPogue, Jason M.; Kaye, Keith S.
errShare
errSave
How do I manage Difficult-to-Treat Pseudomonas aeruginosa infections?: Key Questions for Today’s Clinicians
errClinical Microbiology and Infection
IF8.5
err2025-08-23
err0
PREAI
errJuan P. Horcajada; Ana Gales; Burcu Isler; Keith S. Kaye; Andrea L. Kwa; Cornelia B. Landersdorfer; Maria Milagro Montero; Antonio Oliver; Jason M. Pogue; Ryan K. Shields; Maria Virginia Villegas; Dafna Yahav; David L. Paterson
errShare
errSave
Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity
errClinical Pharmacology & Therapeutics
IF5.5
err2025-06-16
err0
errOAAI
errPatrick O. Hanafin; Ramya Mahadevan; Gauri G. Rao; Alexandre P. Zavascki; Ana Maria Sandri; Andrea Kwa; Marc H. Scheetz; Christine J. Kubin; Jayesh Shah; Benjamin P.Z. Cherng; Michael T. Yin; Jiping Wang; Lu Wang; David P. Calfee; Maureen Bolon; Anthony W. Purcell; Roger L. Nation; Jason M. Pogue; Jian Li; Keith S. Kaye
errShare
errSave
The Antibiotic Pipeline Has Delivered for Drug-Resistant Gram-Negative Pathogens, Now Global Access Must Follow
errCLINICAL INFECTIOUS DISEASES
IF7.3
err2025-06-01
err0
PREAI
errPogue, Jason M.; van Duin, David
errShare
errSave
Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?
errANTIMICROBIAL AGENTS AND CHEMOTHERAPY
IF4.5
err2025-01-28
err0
errOAAI
errDorazio, Ava J.; Kline, Ellen G.; Squires, Kevin M.; Pogue, Jason M.; Van Tyne, Daria; Shields, Ryan K.
errShare
errSave
A Comparison of Different Strategies for Optimizing the Selection of Empiric Antibiotic Therapy for Pneumonia Caused by Gram-Negative Bacteria in Intensive Care Units: Unit-Specific Combination Antibiograms Versus Patient-Specific Risk Factors
errOPEN FORUM INFECTIOUS DISEASES
IF3.8
err2024-10-30
err1
errOAAI
errWangchinda, Walaiporn; Aitken, Samuel L.; Klatt, Megan E.; Lephart, Paul R.; Smith, Aaron B.; Pogue, Jason M.
errShare
errSave
Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa Bacteremia or Pneumonia
errCLINICAL INFECTIOUS DISEASES
IF7.3
err2024-06-21
err6
errOAAI
errShah, Sunish; Kline, Ellen G.; Haidar, Ghady; Squires, Kevin M.; Pogue, Jason M.; Mccreary, Erin K.; Ludwig, Justin; Clarke, Lloyd G.; Stellfox, Madison; Van Tyne, Daria; Shields, Ryan K.
errShare
errSave
Piperacillin/Tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations From the United States Committee on Antimicrobial Susceptibility Testing
errCLINICAL INFECTIOUS DISEASES
IF7.3
err2024-06-21
err1
errOAAI
errLodise, Thomas P.; Bhavnani, Sujata M.; Ambrose, Paul G.; Sader, Helio S.; Andes, David; Pogue, Jason M.
errShare
errSave
Is it time to join the oral antibiotics bandwagon?
errLANCET INFECTIOUS DISEASES
IF31
err2024-05-01
err0
PREAI
errJusto, Julie Ann; Pogue, Jason M.
errShare
errSave
The Growing Threat of NDM-Producing E. Coli With Penicillin-Binding Potein 3 Mutations in the United States-Is There a Potential Role for Durlobactam?
errCLINICAL INFECTIOUS DISEASES
IF7.3
err2024-04-25
err4
PREAI
errAitken, Samuel L.; Pierce, Virginia M.; Pogue, Jason M.; Kline, Ellen G.; Tverdek, Frank P.; Shields, Ryan K.
errShare
errSave
Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections
errJOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
IF3.6
err2024-04-10
err3
PREAI
errWangchinda, Walaiporn; Pogue, Jason M.; Thamlikitkul, Visanu; Leelawattanachai, Pannee; Koomanachai, Pornpan; Pai, Manjunath P.
errShare
errSave
A comparison of strategies for identifying patients at risk for carbapenem-resistant or extended β-lactam-resistant Pseudomonas aeruginosa
errJOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
IF3.6
err2024-04-06
err0
PREAI
errWangchinda, Walaiporn; Kaye, Keith S.; Patel, Twisha S.; Albin, Owen R.; Saravolatz II, Louis; Petrie, Joshua G.; Pogue, Jason M.
errShare
errSave
Tebipenem and Sulopenem: Dynamic Duo or Double Trouble?
errinfectious disease reports
IF2.9
err2024-02-10
err2
errOAAI
errMangum, Blake R.; Pogue, Jason M.; Barber, Katie E.
errShare
errSave
Which trial do we need? Combination antimicrobial therapy for hospital-acquired bacterial pneumonia caused by Pseudomonas aeruginosa
errCLINICAL MICROBIOLOGY AND INFECTION
IF8.5
err2024-02-01
err2
PREAI
errAlbin, Owen R.; Pogue, Jason M.; Wunderink, Richard G.; Kaye, Keith S.
errShare
errSave
Impact of Reducing Time-to-Antibiotics on Sepsis Mortality, Antibiotic Use, and Adverse Events
errANNALS OF THE AMERICAN THORACIC SOCIETY
IF5.4
err2024-01-01
err3
PREAI
errDonnelly, John P.; Seelye, Sarah M.; Kipnis, Patricia; McGrath, Brenda M.; Iwashyna, Theodore J.; Pogue, Jason; Jones, Makoto; Liu, Vincent X.; Prescott, Hallie C.
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
D
David L. Paterson
H-index: 131 · Papers: 949
M
Marin H. Kollef
H-index: 128 · Papers: 906
R
Ronald N. Jones
H-index: 127 · Papers: 1.6K
R
Robert A. Bonomo
H-index: 115 · Papers: 1.1K
D
David R. Andes
H-index: 110 · Papers: 596
View more